Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
about
Imatinib in chronic myeloid leukemia: an overviewERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyPTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in miceSmac mimetics: implications for enhancement of targeted therapies in leukemiaA non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugTargeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.Gene expression changes associated with progression and response in chronic myeloid leukemia.Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cellsTargeted inhibition of kinases in cancer therapyAntileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.Is there a cloud in the silver lining for imatinib?Role of Pten in leukemia stem cellsThe novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibStem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitorsChronic myeloid leukemia: mechanisms of resistance and treatment.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureBeneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive RhabdomyosarcomaABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesA NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignanciesManagement of imatinib-resistant patients with chronic myeloid leukemia.Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1.Therapy of chronic myeloid leukemia: twilight of the imatinib era?New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Roles of p53 in various biological aspects of hematopoietic stem cells.Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.
P2860
Q26865086-C1FD4C4D-F5DA-4DD6-BFF3-7F2E164DF67EQ33476874-70A11CBA-F01E-4E13-A2C3-B382B7FD559BQ33608760-80655FF0-2522-4F9E-AEDC-E3A9111326A9Q33683159-EEFBACF4-188F-4028-927D-5EF8B1EF580EQ33767209-E5B42B2D-C3B9-4CBD-9B80-22D1CD2FC394Q33828334-51A813D8-70CF-4263-9197-43321E0C645FQ33844109-1F1C8BBD-84A6-4742-A0A1-CB2BA1FBB4A5Q34064832-182839C3-9EC8-45DA-B04B-F8CECDCC9047Q34065271-92BF7759-7204-4C60-B076-037F820B5F40Q34277769-E6BFE804-34CA-40BB-8817-D6A6009CB23FQ34479561-C3DBFC3C-55DC-486D-82B7-9C28AD854095Q34483497-3FF7F33F-E4BD-4049-9CCA-2104237B8F43Q34683348-5F779B4F-E482-4976-9CF8-156284EB4973Q34972671-CE9D04A4-D8A6-4428-B94A-A7C5F96EBD03Q35037415-BE9A20D2-80E2-43D9-9BF6-480F223490A1Q35097392-309FBD46-EC4A-4EF2-8EDE-912F17DA6C2AQ35169570-37034B22-350C-4754-AEA8-15A5899F51DDQ35377275-AAF18FB7-BDF2-4226-AA9A-BBA507CA0010Q35459748-2533094C-837F-4858-8B4C-7BE3E533DE41Q35595795-A0A7DDD0-063A-4456-97F5-DF9CF0330514Q35596200-24646AFC-6BB3-40A0-BC20-7FF8ACC249B2Q35642790-9F5EDE7B-A346-4AB9-8F0D-D3B9A6757065Q35849543-9F3B793C-F327-445A-B659-4DA8AABF4549Q35900937-59A93391-FDBB-4CF2-9448-54E64D69C67BQ36093810-8CB27B50-E44E-4536-90A3-618F2D8BF9A3Q36106559-B712B62C-3679-4166-9895-71777EB3D3C2Q36414254-6A9D4673-92D1-4EAC-9F25-80591CDC0F1FQ36776423-5DF53973-25FB-460F-95BB-5B6987B7A3C9Q37369672-103D6F23-A8C7-4A10-A0EF-EEEE907C4323Q37390619-E30800A3-EB20-4758-8A44-302ABE016E28Q37593435-4F20A0EE-74ED-4C99-BE02-28B905D8C5AFQ37836938-F2BCABE4-E631-4697-83A1-B0952C026B0FQ38025085-4CFD2FE9-23E3-4449-8AE2-A021661E44AAQ38133575-6307B3D7-65E3-43B0-9C62-123493A2AA62Q39122858-5286DA39-15EA-4612-8FD7-4C3039951E54Q39176607-C859D8F7-C461-4485-A4AA-E46624CDA288Q39596672-5CEECC7D-3019-4DB4-B7C9-FC60E87F5A05Q40357233-F129A83B-B8E4-437E-9EA7-0177957ED735Q40971143-0C96CE90-B991-4674-91BC-192D77CBC13FQ41842515-6EC91231-20B4-4D9D-A566-74E76CD8F639
P2860
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Mechanism of resistance to the ...... rmed hematopoietic cell lines.
@en
type
label
Mechanism of resistance to the ...... rmed hematopoietic cell lines.
@en
prefLabel
Mechanism of resistance to the ...... rmed hematopoietic cell lines.
@en
P1433
P1476
Mechanism of resistance to the ...... ormed hematopoietic cell lines
@en
P2093
Griffin JD
Weisberg E
P304
P407
P577
2000-06-01T00:00:00Z